Please enable JavaScript to continue using this application.

Compare $IMDX vs $UNCY | Chartloom

Compare

$IMDX vs $UNCY

Insight Molecular Diagnostics Inc · Unicycive Therapeutics Inc

IMDX

Insight Molecular Diagnostics Inc

UNCY

Unicycive Therapeutics Inc

Compare $IMDX vs $UNCY

Comparing Insight Molecular Diagnostics Inc and Unicycive Therapeutics Inc

IMDXInsight Molecular Diagnostics Inc

UNCYUnicycive Therapeutics Inc

IMDXInsight Molecular Diagnostics Inc

Market cap

$109M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

58.81x

Rev growth (TTM)

-60.8%

YTD performance

-52.9%

52W performance

-8.4%

FCF yield

-28.4%

UNCYUnicycive Therapeutics Inc

Market cap

$110M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.31x

Rev growth (TTM)

—

YTD performance

-29.1%

52W performance

-13.8%

FCF yield

-25.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IMDX

UNCY

Detailed metrics comparison

IMDX

Insight Molecular Diagnostics Inc

UNCY

Unicycive Therapeutics Inc

Market Cap

IMDX$109M

UNCY$110M

Enterprise Value

IMDX$92M

UNCY$66M

Price

IMDX$3.37

UNCY$4.11

P/E Ratio

IMDXN/A

UNCYN/A

P/S Ratio

IMDX65.16x

UNCY31.15x

EV/Sales

IMDX54.99x

UNCY0.00x

EV/EBITDA

IMDX0.00x

UNCY0.00x

P/B Ratio

IMDX102.52x

UNCY2.21x

P/FCF Ratio

IMDXN/A

UNCYN/A

EV/FCF

IMDX-2.97x

UNCY-2.35x

PEG Ratio

IMDXN/A

UNCYN/A

Forward P/E (NTM)

IMDXN/A

UNCYN/A

Forward P/S (NTM)

IMDX58.81x

UNCY0.31x

Revenue (TTM)

IMDX$2M

UNCY$0

Revenue Growth (YoY)

IMDX-60.8%

UNCYN/A

Forward Rev Growth

IMDX593.7%

UNCY37378.0%

Gross Margin (TTM)

IMDX48.3%

UNCY0.0%

Operating Margin (TTM)

IMDX0.0%

UNCY0.0%

EBITDA Margin (TTM)

IMDX-1986.2%

UNCY0.0%

Net Margin (TTM)

IMDX-2955.6%

UNCY0.0%

FCF Margin (TTM)

IMDX-1848.8%

UNCYN/A

Net Income (TTM)

IMDX$-49M

UNCY$-35M

FCF (TTM)

IMDX$-31M

UNCY$-28M

EPS (TTM)

IMDX-$1.34

UNCY-$1.31

ROE (TTM)

IMDX-42668.0%

UNCY-8881.0%

ROA (TTM)

IMDX-14147.0%

UNCY-5966.0%

ROIC (TTM)

IMDX-37415.0%

UNCY-8881.0%

Cash

IMDX$18M

UNCY$44M

Debt

IMDX$766K

UNCY$0

Net Cash/Debt

IMDX$17M

UNCY$44M

Current Ratio (TTM)

IMDX2.00x

UNCY3.81x

Quick Ratio (TTM)

IMDX1.82x

UNCY3.28x

Debt/Equity (TTM)

IMDX0.92x

UNCY0.00x

Debt/Assets (TTM)

IMDX0.0%

UNCY0.0%

Interest Coverage (TTM)

IMDXN/A

UNCYN/A

Net Debt/EBITDA (TTM)

IMDX0.00x

UNCY0.00x

Beta

IMDX1.86

UNCY1.78

52W Performance

IMDX-8.4%

UNCY-13.8%

YTD Performance

IMDX-52.9%

UNCY-29.1%

% from 52W High

IMDX-60.4%

UNCY-53.0%

% from 52W Low

IMDX39.3%

UNCY4.6%

Asset Turnover (TTM)

IMDX0.05x

UNCY0.05x

FCF Yield (TTM)

IMDX-28.4%

UNCY-25.4%

Earnings Yield (TTM)

IMDX-45.4%

UNCY-32.1%

Dividend Yield (TTM)

IMDXN/A

UNCYN/A

Rule of 40

IMDX-1,909.6

UNCY0.0

EV/GP/RG

IMDX10.54

UNCYN/A

Ticker research

View IMDX research View UNCY research

Metric	IMDX Insight Molecular Diagnostics Inc	UNCY Unicycive Therapeutics Inc
Market & Valuation
Market Cap	$109M	$110M
Enterprise Value	$92M	$66M
Price	$3.37	$4.11
P/E Ratio	N/A	N/A
P/S Ratio	65.16x	31.15x
EV/Sales	54.99x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	102.52x	2.21x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.97x	-2.35x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	58.81x	0.31x
Revenue & Growth
Revenue (TTM)	$2M	$0
Revenue Growth (YoY)	-60.8%	N/A
Forward Rev Growth	593.7%	37378.0%
Profitability
Gross Margin (TTM)	48.3%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1986.2%	0.0%
Net Margin (TTM)	-2955.6%	0.0%
FCF Margin (TTM)	-1848.8%	N/A
Net Income (TTM)	$-49M	$-35M
FCF (TTM)	$-31M	$-28M
EPS (TTM)	-$1.34	-$1.31
ROE (TTM)	-42668.0%	-8881.0%
ROA (TTM)	-14147.0%	-5966.0%
ROIC (TTM)	-37415.0%	-8881.0%
Financial Health
Cash	$18M	$44M
Debt	$766K	$0
Net Cash/Debt	$17M	$44M
Current Ratio (TTM)	2.00x	3.81x
Quick Ratio (TTM)	1.82x	3.28x
Debt/Equity (TTM)	0.92x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.86	1.78
52W Performance	-8.4%	-13.8%
YTD Performance	-52.9%	-29.1%
% from 52W High	-60.4%	-53.0%
% from 52W Low	39.3%	4.6%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.05x
FCF Yield (TTM)	-28.4%	-25.4%
Earnings Yield (TTM)	-45.4%	-32.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,909.6	0.0
EV/GP/RG	10.54	N/A
Ticker research	View IMDX research	View UNCY research

Valuation

P/S Ratio

UNCY

31.15x

IMDX

65.16x

EV/FCF

IMDX

-2.97x

UNCY

-2.35x

Growth & revenue

Revenue Growth TTM

IMDX

-60.8%

Forward Revenue Growth

UNCY

37378.0%

IMDX

593.7%

Profitability & performance

Gross Margin

IMDX

48.3%

UNCY

0.0%

ROE

UNCY

-8881.0%

IMDX

-42668.0%

FCF Yield %

UNCY

-25.4%

IMDX

-28.4%

52-Week Performance

IMDX

-8.4%

UNCY

-13.8%

Detailed metrics comparison

IMDX

Insight Molecular Diagnostics Inc

UNCY

Unicycive Therapeutics Inc

Market Cap

IMDX$109M

UNCY$110M

Enterprise Value

IMDX$92M

UNCY$66M

Price

IMDX$3.37

UNCY$4.11

P/E Ratio

IMDXN/A

UNCYN/A

P/S Ratio

IMDX65.16x

UNCY31.15x

EV/Sales

IMDX54.99x

UNCY0.00x

EV/EBITDA

IMDX0.00x

UNCY0.00x

P/B Ratio

IMDX102.52x

UNCY2.21x

P/FCF Ratio

IMDXN/A

UNCYN/A

EV/FCF

IMDX-2.97x

UNCY-2.35x

PEG Ratio

IMDXN/A

UNCYN/A

Forward P/E (NTM)

IMDXN/A

UNCYN/A

Forward P/S (NTM)

IMDX58.81x

UNCY0.31x

Revenue (TTM)

IMDX$2M

UNCY$0

Revenue Growth (YoY)

IMDX-60.8%

UNCYN/A

Forward Rev Growth

IMDX593.7%

UNCY37378.0%

Gross Margin (TTM)

IMDX48.3%

UNCY0.0%

Operating Margin (TTM)

IMDX0.0%

UNCY0.0%

EBITDA Margin (TTM)

IMDX-1986.2%

UNCY0.0%

Net Margin (TTM)

IMDX-2955.6%

UNCY0.0%

FCF Margin (TTM)

IMDX-1848.8%

UNCYN/A

Net Income (TTM)

IMDX$-49M

UNCY$-35M

FCF (TTM)

IMDX$-31M

UNCY$-28M

EPS (TTM)

IMDX-$1.34

UNCY-$1.31

ROE (TTM)

IMDX-42668.0%

UNCY-8881.0%

ROA (TTM)

IMDX-14147.0%

UNCY-5966.0%

ROIC (TTM)

IMDX-37415.0%

UNCY-8881.0%

Cash

IMDX$18M

UNCY$44M

Debt

IMDX$766K

UNCY$0

Net Cash/Debt

IMDX$17M

UNCY$44M

Current Ratio (TTM)

IMDX2.00x

UNCY3.81x

Quick Ratio (TTM)

IMDX1.82x

UNCY3.28x

Debt/Equity (TTM)

IMDX0.92x

UNCY0.00x

Debt/Assets (TTM)

IMDX0.0%

UNCY0.0%

Interest Coverage (TTM)

IMDXN/A

UNCYN/A

Net Debt/EBITDA (TTM)

IMDX0.00x

UNCY0.00x

Beta

IMDX1.86

UNCY1.78

52W Performance

IMDX-8.4%

UNCY-13.8%

YTD Performance

IMDX-52.9%

UNCY-29.1%

% from 52W High

IMDX-60.4%

UNCY-53.0%

% from 52W Low

IMDX39.3%

UNCY4.6%

Asset Turnover (TTM)

IMDX0.05x

UNCY0.05x

FCF Yield (TTM)

IMDX-28.4%

UNCY-25.4%

Earnings Yield (TTM)

IMDX-45.4%

UNCY-32.1%

Dividend Yield (TTM)

IMDXN/A

UNCYN/A

Rule of 40

IMDX-1,909.6

UNCY0.0

EV/GP/RG

IMDX10.54

UNCYN/A

Ticker research

View IMDX research View UNCY research

Metric	IMDX Insight Molecular Diagnostics Inc	UNCY Unicycive Therapeutics Inc
Market & Valuation
Market Cap	$109M	$110M
Enterprise Value	$92M	$66M
Price	$3.37	$4.11
P/E Ratio	N/A	N/A
P/S Ratio	65.16x	31.15x
EV/Sales	54.99x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	102.52x	2.21x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.97x	-2.35x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	58.81x	0.31x
Revenue & Growth
Revenue (TTM)	$2M	$0
Revenue Growth (YoY)	-60.8%	N/A
Forward Rev Growth	593.7%	37378.0%
Profitability
Gross Margin (TTM)	48.3%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1986.2%	0.0%
Net Margin (TTM)	-2955.6%	0.0%
FCF Margin (TTM)	-1848.8%	N/A
Net Income (TTM)	$-49M	$-35M
FCF (TTM)	$-31M	$-28M
EPS (TTM)	-$1.34	-$1.31
ROE (TTM)	-42668.0%	-8881.0%
ROA (TTM)	-14147.0%	-5966.0%
ROIC (TTM)	-37415.0%	-8881.0%
Financial Health
Cash	$18M	$44M
Debt	$766K	$0
Net Cash/Debt	$17M	$44M
Current Ratio (TTM)	2.00x	3.81x
Quick Ratio (TTM)	1.82x	3.28x
Debt/Equity (TTM)	0.92x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.86	1.78
52W Performance	-8.4%	-13.8%
YTD Performance	-52.9%	-29.1%
% from 52W High	-60.4%	-53.0%
% from 52W Low	39.3%	4.6%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.05x
FCF Yield (TTM)	-28.4%	-25.4%
Earnings Yield (TTM)	-45.4%	-32.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,909.6	0.0
EV/GP/RG	10.54	N/A
Ticker research	View IMDX research	View UNCY research